|
Repurposing a Potent MDM2 Inhibitor for Leukemia Treatment
Application
VERU-111, also known as sabizabulin, is a potent microtubule inhibitor and, notably, an MDM2 inhibitor. This repurposed compound demonstrates remarkable efficacy in the treatment of Acute Myeloid Leukemia (AML).
Key Benefits
Unique dual-action functionality as a microtubule and MDM2 inhibitor.
Successful inhibition of MDM2, an oncogene...
Published: 4/11/2024
Contributor(s): Deborah DeRyckere, Muxiang Zhou, Lu Bing Gu, Douglas Graham, Tao Liu
|
|
Pre-B Acute Lymphoblastic Leukemia Cell Line EU-4
Application
Cancer cell line derived from a pediatric patient with early B-cell precursor (Pre-B) acute lymphoblastic leukemia with myeloid phenotype.
Key Benefits
Does not express p53 and expresses wild-type MDM2.
Expresses wild-type Bax, over-expresses Bcl-xl, and does not express Bcl-2.
Can be used as a tool for gene transfection assays in...
Published: 3/1/2024
Contributor(s): Muxiang Zhou, Lu Bing Gu
|
|
Early Pre-B Acute Lymphoblastic Leukemia Cell Line EU-1
Application
Cancer cell line derived from a relapsed pediatric patient with early B-cell precursor (Pre-B) acute lymphoblastic leukemia.
Key Benefits
Well-characterized continuous leukemia-lymphoma cell line.
Expresses wild-type p53 and over-expresses MDM2 oncoprotein.
Expresses wild-type Bcl-2, Bcl-xl, and Bax.
Technical Summary
p53 is...
Published: 3/1/2024
Contributor(s): Muxiang Zhou, Lu Bing Gu
|
|
Early Pre-B Acute Lymphoblastic Leukemia Cell Line EU-6
Application
Cancer cell line derived from a relapsed pediatric patient with early B-cell precursor (Pre-B) acute lymphoblastic leukemia.
Key Benefits
Well-characterized to have a point mutation of the p53 gene at codon 273.
Expresses wild-type Bax, Bcl-xl, and Bcl-2.
Well used tool for p53 studies in leukemia.
Technical Summary
p53 is a tumor...
Published: 3/1/2024
Contributor(s): Muxiang Zhou, Lu Bing Gu
|